<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02136303</url>
  </required_header>
  <id_info>
    <org_study_id>BO 1511/8-1</org_study_id>
    <nct_id>NCT02136303</nct_id>
  </id_info>
  <brief_title>Regional Kale as Source of Lutein and Zeaxanthin to Improve Vision of AMD-patients</brief_title>
  <acronym>KALESIGHT</acronym>
  <official_title>Regional Kale as Source of Lutein and Zeaxanthin to Improve Vision of Patients With Age-related Macular Degeneration - an Alternative to Supplements With Isolated Xanthophylls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The age-related macular degeneration (AMD) is an age-dependent, multi-factorial disease. In
      Western industrial countries, it is the main cause of visual impairments. In Germany,
      approximately 4.5 million people suffer from AMD. Genetic as well as nutritional aspects are
      mainly important in AMD development. Until now, AMD-patients are advised to use supplements
      based on the carotenoids lutein and zeaxanthin, comprised in high doses and in isolated form.
      Results showing the effects of food items (kale, spinach) rich in lutein on improvement of
      vision are scarce. And how much is needed within the diet? Within the planned project, human
      intervention studies will investigate whether an oil-based kale extract or fresh kale can be
      used to improve vision of AMD-patients and persons aged 50+ (without AMD). The first study
      will use volunteers without AMD (&gt;18 y) to investigate if there is a dose-dependent effect of
      lutein and zeaxanthin (out of a kale extract) on macular pigment optical density (MPOD). This
      study will also compare the bioavailability of the carotenoids from the extract and from a
      supplement. A second study (also using volunteers without AMD, &gt;18 y) will compare the
      bioavailability of lutein and zeaxanthin from the extract and from kale purée. The third
      study will investigate the effect of the oil-based kale extract on improvements of MPOD and
      vision of AMD-patients and of a control group (volunteers 50+ without AMD).

      Usually, the intestinal absorption of lutein and zeaxanthin is determined by analyzing
      changes in concentrations in blood plasma. A fast, non-invasive sampling will be evaluated to
      check the efficacy of an increased uptake of lutein. Thus, the project will test the
      usability of buccal mucosa cells to detect metabolic changes after an uptake of carotenoids.
      Besides, the determination of carotenoid contents in skin will be checked on its use as
      biomarker of carotenoids in plasma and macula.

      Thus, the planned research project will evaluate two non-invasive markers of exposition on
      their usability as markers of absorption of lutein and zeaxanthin in blood and macula. In
      addition, the minimally needed dosage of lutein and zeaxanthin for AMD prevention will be
      determined to reduce the possible risk of currently recommended doses of these compounds. The
      project will also present alternatives (kale extract, kale purée) for AMD prevention and to
      improve vision to be used instead of currently used high-dose supplements.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in macular pigment optical density MPOD [ODU: optical density units]</measure>
    <time_frame>baseline and after 4/8 weeks, baseline and after 6/12/18/24 weeks</time_frame>
    <description>Changes from baseline to various time points for different parameters of MPOD will be measured: changes in mean MPOD [ODU], changes in max. MPOD [ODU], changes in volume of MPOD [ODU x (degree)2], changes in area of MPOD [degree2]</description>
  </primary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Changes in Macular Pigment Optical Density</condition>
  <arm_group>
    <arm_group_label>S1-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule with all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S1-1L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule containing 1 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S1-2L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule containing 2 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S1-5L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule containing 5 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S2-Kale_extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S2-Kale_purée</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S3-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S3-AMD-Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S3-non-AMD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S1-Placebo-Tagetes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>capsule containing all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S1-1L-Tagetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule containing 1 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S1-2L-Tagetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule containing 2 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S1-5L-Tagetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule containing 5 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S1-10L-Tagetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule containing 10 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>S1: Dosage-dependency</intervention_name>
    <description>kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein</description>
    <arm_group_label>S1-Placebo</arm_group_label>
    <arm_group_label>S1-1L</arm_group_label>
    <arm_group_label>S1-2L</arm_group_label>
    <arm_group_label>S1-5L</arm_group_label>
    <arm_group_label>S1-Placebo-Tagetes</arm_group_label>
    <arm_group_label>S1-1L-Tagetes</arm_group_label>
    <arm_group_label>S1-2L-Tagetes</arm_group_label>
    <arm_group_label>S1-5L-Tagetes</arm_group_label>
    <arm_group_label>S1-10L-Tagetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>S2: Kale extract versus kale purée</intervention_name>
    <arm_group_label>S2-Kale_extract</arm_group_label>
    <arm_group_label>S2-Kale_purée</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>S3: Kale extract: AMD-patients</intervention_name>
    <arm_group_label>S3-Placebo</arm_group_label>
    <arm_group_label>S3-AMD-Patients</arm_group_label>
    <arm_group_label>S3-non-AMD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy, &gt; 18 years, written consent

        Exclusion Criteria:

          -  uptake of dietary supplements, glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Volker Böhm, Dr.</last_name>
    <phone>+49-(0)3641-949633</phone>
    <email>Volker.Boehm@uni-jena.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Eye Hospital, Friedrich Schiller University Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Arnold C, Winter L, Fröhlich K, Jentsch S, Dawczynski J, Jahreis G, Böhm V. Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmol. 2013 May;131(5):564-72. doi: 10.1001/jamaophthalmol.2013.2851.</citation>
    <PMID>23519529</PMID>
  </results_reference>
  <results_reference>
    <citation>Arnold C, Jentsch S, Dawczynski J, Böhm V. Age-related macular degeneration: Effects of a short-term intervention with an oleaginous kale extract--a pilot study. Nutrition. 2013 Nov-Dec;29(11-12):1412-7. doi: 10.1016/j.nut.2013.05.012.</citation>
    <PMID>24103519</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2014</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Volker Boehm</investigator_full_name>
    <investigator_title>PD Dr. Volker Böhm</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

